Table 3.
Frequency and reasons for discontinuing etanercept therapy, including the sensitivity analysis results
| Etanercept originator | Sensitivity analysisa | Etanercept biosimilar | |
|---|---|---|---|
| Total | 1009 | 1009 | 797 |
| Follow-up in BSRBR-RA since registration, years | 5.0 (3.4–6.2) | 5.0 (3.4–6.2) | 2.7 (1.8–4.0) |
| One-year Kaplan–Meier drug survival (%) (95% CI) | 68 (65, 71) | 71 (68, 74) | 76 (73, 79) |
| Discontinued treatment, n (%) | 819 (81) | 530 (53) | 330 (41) |
| Time to discontinuation, months | 18 (7–41) | 11 (5–26) | 10 (5–18) |
| Reasons for treatment discontinuation, n (% of whole cohort) | |||
| Ineffectiveness | 208 (21) | 208 (21) | 158 (20) |
| Adverse events including deaths | 219 (22) | 219 (22) | 108 (14) |
| Remission | 3 (<1) | 3 (<1) | 6 (1) |
| Switched to a biosimilar | 189 (19) | – | – |
| Otherb | 65 (6) | 65 (6) | 39 (5) |
| Missing | 35 (3) | 35 (3) | 19 (2) |
| Discontinuation | |||
| Unadjusted [HR (95% CI)] | 1.69 (1.48, 1.92)* | 1.21 (1.05, 1.39)* | [base] |
| Propensity decile adjustedc [HR (95% CI)] | 1.62 (1.41, 1.85)* | 1.15 (0.99, 1.33) | [base] |
All values are n (%), or median (interquartile range), unless stated otherwise.
Sensitivity analysis for the etanercept originator cohort to censor patients who switched to a biosimilar.
Other reasons for treatment discontinuations were unique to the patient.
Adjusted by propensity deciles—baseline variables in the propensity score included age, gender, ethnicity, disease duration, smoking status, BMI, number of comorbidities, joint surgery history, anti-CCP positivity, RF positivity, baseline MTX use, baseline steroid use, baseline conventional synthetic DMARD use, number of previous conventional synthetic DMARDs, DAS of 28-joints score, swollen joint count, tender joint count, CRP, ESR, patient’s global assessment and HAQ score.
P < 0.05. BSRBR-RA: British Society for Rheumatology Biologics Register for RA; HR: hazard ratio.